02563 BIOSTAR PHARM-B
- 26.100
- +5.300+25.48%
BIOSTAR PHARM-B News
Hong Kong stocks unusual movement | Hua Hao Zhongtian Pharmaceuticals-B (02563) rose nearly 14% on the second day of listing. The core product You Tidelong Injection has been included in medical insurance.
Huahao Zhongtian Pharmaceutical - B (02563) rose nearly 14% on the second day of listing, as of the time of publication, up 7.21%, trading at 22.3 Hong Kong dollars, with a turnover of 12.9399 million Hong Kong dollars.
After boosting the stock price by 30% with the "routine callback", what supports the market cap of nearly 8 billion Hong Kong dollars for Huahao Zhongtian Pharmaceutical - B (02563)?
In short, the weak profit performance, relying solely on a single core product for research and development, creates a certain degree of uncertainty in the future performance of Huahao Zhongtian Pharmaceutical. In addition, with the poor performance of the synthetic biology sector globally on the secondary market, Huahao Zhongtian Pharmaceutical needs to continuously optimize its fundamentals if it wants to prove itself in the Hong Kong stock market, while strengthening innovation and further enhancing its hematopoietic capacity.
Hong Kong Stocks Extend Losses; Beijing Biostar Pharmaceuticals Soars 30% in Debut
Hong Kong stock market anomaly | The new stock Huahao Zhongtian Medicine-B (02563) rose by more than 60%. The company is committed to developing innovative drugs for tumors. Urodelone injection is the core product.
The new stock of Huahao Zhongtian Pharmaceutical-B (02563) debuted with a high opening and continued to rise. Intraday gain expanded by over 60%. As of the press time, it increased by 52.81% to 24.45 Hong Kong dollars, with a turnover of 48.9312 million Hong Kong dollars.
Hua Hao Zhongtian Pharmaceutical - B (2563.HK): Driven by synthetic biology technology, it is creating a new force of innovative drugs for cancer.
The Federal Reserve announced a 50 basis points rate cut on September 18, 2024, marking a shift from a tightening cycle to an easing cycle in monetary policy. Meanwhile, the Chinese government also implemented a series of fiscal and monetary policies to boost domestic demand, including issuing ultra-long special national bonds and reducing reserve requirements and interest rates by the central bank. The implementation of these policies released liquidity, providing support to the capital markets. Against this backdrop, the healthcare sector in the Hong Kong stock market was boosted and performed well in this round of rebound. In the third quarter of 2024, the fund holdings in the healthcare industry continued to rise, with the size of healthcare funds reaching 314.1 billion yuan, an increase of 15% compared to the previous period.
On the first day of new shares | Huahao Zhongtian Medicine-B (02563) listed for the first time, opening 34.38% higher in the morning.
Huahao Zhongtian Pharmaceutical-B (02563) is listed for the first time. The announcement shows that the pricing per share is 16 Hong Kong dollars, with a total issuance of 14.588 million shares, and 200 shares per lot. The net proceeds will be approximately 0.19589 billion Hong Kong dollars. As of the time of writing, it has risen by 34.38% to 21.5 Hong Kong dollars, with a turnover of 22.4505 million Hong Kong dollars.
Futu Morning Post | Citigroup strategist talks about the 'Trump winning trade', a good opportunity to profit from the surge in US stocks; AI capital spending continues to expand! Microsoft, Meta both fell after hours.
USA Treasury Department's heavyweight quarterly refinancing announcement: Maintain long-term bond auction scale and guidance unchanged; the U.S. presidential election is undecided, the dollar hedging cost has risen to the highest since 2022; it will impact 3000 dollars next year! Goldman Sachs raises gold price expectations, stating that central bank demand expectations have quadrupled.
Hong Kong IPO Update: Today, Huahao Zhongtian Pharmaceutical listed.
As of October 31, Guolonghui reported that Huahao Zhongtian Pharmaceutical (2563.HK) was listed today, with no ipo subscription available.
China Tong Hong Kong Stock Investment Diary | October 31st
Hong Kong Stock Investment Journal | October 31, 2024
Huahao Zhongtian Pharmaceuticals-B (02563) set a limit price for public offering and received 21.45 times oversubscription.
Huahao Zhongtian Pharmaceutical-B (02563) announced the results of the distribution, with the company planning to globally issue 14.588 million shares of stock, public...
Dark Pool Intelligence: "Cancer innovative drug developer" Huahao Zhongtian Medicine-B rose 25%, with a total market value of 7.292 billion Hong Kong dollars.
Futu news on October 30th: $China Haotian Pharmaceuticals-B (02563.HK)$ opened dark today, closed up X%, at X Hong Kong dollars, with a turnover of X million Hong Kong dollars, a total market value of X billion Hong Kong dollars; X shares per lot, excluding handling fees, earning X Hong Kong dollars per lot. Market source: Futu Securities. Highlighted investment industry position leading: Established in March 2003, jiangsu lopal tech is a major global manufacturer of lithium iron phosphate cathode materials, and also a well-known mainland China manufacturer of fine chemicals for automotive use. In terms of sales volume in 2023, jiangsu lopal tech is the world's fourth-largest manufacturer of lithium iron phosphate cathode materials, with a market share of 6.5%.
Dark pool intelligence| 'Oncology innovative drug developer' Huahao Zhongtian Medicine-B is up 24.88%, with a total market value exceeding 7.2 billion Hong Kong dollars.
Futu news on October 30th, "The first stock of synthetic biology medicine" $ Huahao Zhongtian Medicine-B (02563.HK) $ opened dark today, currently up by X%, trading at X Hong Kong dollars, turnover X million Hong Kong dollars, total market value of X billion Hong Kong dollars. Market source: CSI All Share Investment Banking &. Overview Huahao Zhongtian Medicine, established in 2002, is a biopharmaceutical company driven by synthetic biology technology, dedicated to developing innovative drugs for tumors, and has successfully developed three core technology platforms focusing on the research and development of new drugs from microbial metabolites. As of October 14, 2024, Huahao Zhongtian Medicine has one commercialized product.
New stock analysis | The public offering of shares has met with a cold response. Why is Huahao Zhongtian Medical-B (02563) not favored by the market?
After years on the market, the core product has still not escaped losses. What should Hua Hao Zhong Tian Pharmaceuticals-B (02563) do next?
One-week lookahead | Heavyweight financial reports coming! Technology giants such as apple, microsoft are unveiling one after another; USA economic data bombardment one after another! Non-farm payroll report finale on Friday.
Multiple countries will announce their GDP for the third quarter, with the USA's economy expected to achieve an annualized growth rate of 3.3% in the third quarter; Bank of Japan interest rate decision: expected to maintain short-term interest rates unchanged, gradually reducing the scale of bond purchases.
Hua Hao Zhongtian Pharmaceutical-B (2563.HK) initiates IPO: Revenue growth exceeds 100%, claiming to be the "first stock in synthetic biology".
Since entering 2024, the innovative drug industry has continued to release bullish signals.
Express News | The Hong Kong new stock market is heating up, with many star stocks IPOs being well received.
Express News | Hong Kong IPO Update: Today, Deheng Marine Transportation and 3 other stocks are in the subscription period.
Hong Kong IPO Dynamics: siasun robot&automation Horizon Robotics Listed Today.
October 24th, GeLongHui. Today, Horizon Robotics (9660.HK) went public, jiangsu lopal tech. (2465.HK), and Huahao Zhongtian Medicine (2563.HK) are in the subscription period.
China Tong Hong Kong Stock Investment Journal | October 24th
Hong Kong Stock Investment Journal | October 24, 2024
Hong Kong Stocks Rebound on Earnings Optimism, Potential Stabilization Fund; China Resources Beverage Surges 15% in Trading Debut
Analysis
Price Target
No Data
No Data